was announced in molecular medicine, Researchers at the Lawson Institute for Health found a unique biomarker in the blood of patients with the post-COVID-19 condition (long COVID). The team is now working on developing the first blood test of its kind that can be used to diagnose his COVID over time. This discovery may also lead to new treatments for this condition.
Long-term COVID occurs when someone experiences symptoms such as fatigue, cognitive problems, shortness of breath, and gastrointestinal problems after the initial diagnosis of COVID-19. It can take up to 12 months for the condition to develop. Science Center (LHSC). “Physicians currently rely solely on symptoms to diagnose conditions, but our study provides a unique profile of blood biomarkers that can be used in clinical trials.”
Researchers studied 140 blood samples from participants at the LHSC and St Joseph Health Care London, including St Joseph’s Post-Acute COVID-19 Programme. Participants were hospitalized patients with acute infection of COVID-19 and her COVID patients who were presumed healthy.
“We decided to study the blood vessels that connect all body systems to look for changes after acute infection,” explains Dr. Fraser, who is also a professor at Schulich School of Medicine and Dentistry at Western University.
The team found rapid changes in blood vessels in people with presumed long COVID-19 after confirmed COVID-19 infection. They also found that 14 vascular-related blood biomarkers were elevated in patients with longer duration of COVID. With the help of machine learning, they found that he could classify long her COVID with 96% accuracy using his two biomarkers called ANG-1 and P-SEL.
Dr. Michael Nicholson, associate scientist at Lawson, pulmonologist at St. Joseph’s University, and associate professor of medicine and dentistry at Schurich, said: “This study enhances his understanding of COVID over time with the potential to improve diagnosis and patient care.”
The advantage of biomarkers is that they not only help diagnose disease, but also provide insight into potential treatments. The team is now focused on using their findings to create clinical diagnostic tests with the goal of exploring treatments.
“A point-of-care diagnostic test will allow us to confidently diagnose long-term COVID and ultimately develop targeted treatments for these vascular changes we discover,” says Dr. Fraser. . “The ultimate goal is to improve patient outcomes after his COVID diagnosis over the long term.”
This research was supported by funding from the London Health Science Foundation, the London Community Foundation and the AMOSO Innovation Fund. It builds on his growing COVID-19 research by a scientist at the Lawson Health Research Institute.
The lead author of the study, Maitray Patel, is a PhD student at Western University’s Schulich School of Medicine & Dentistry. Patel worked on blood analysis under the supervision of Dr. Doug Fraser and Mark Daly.
Celine Zadorsky is a Communications Consultant at the Lawson Health Research Institute.
Post view: 8
London researchers discover new way to diagnose long COVID
Source link London researchers discover new way to diagnose long COVID